Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
Multiple Myeloma
DRUG: Elotuzumab|DRUG: Dexamethasone|DRUG: Dexamethasone|DRUG: Lenalidomide|DRUG: Bortezomib|DRUG: Pomalidomide|DRUG: Nivolumab
The number of participants who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected., Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.
All serious adverse events (SAEs) will be collected., Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.|All Grade 5 adverse events (AEs) will be collected., Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.|All adverse events (AEs) previously not reported will be collected., Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.|All adverse events (AEs) leading to discontinuation will be collected., Maximum duration is until all participants have discontinued study drugs, or until all participants are treated for up to 2 years, unless BMS chooses to extend the study.
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.